These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2849127)

  • 21. Competition for polyamine uptake into rat lung slices by WR2721 and analogues.
    Wyatt I; Moore RB; Smith LL
    Int J Radiat Biol; 1989 Mar; 55(3):463-72. PubMed ID: 2564041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium hydrogen-S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913): toxicity and bone marrow radioprotection.
    Mendiondo OA; Connor AM; Grigsby P
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):553-5. PubMed ID: 6286552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of WR-2721.
    Shaw LM; Glover D; Turrisi A; Brown DQ; Bonner HS; Norfleet AL; Weiler C; Glick JH; Kligerman MM
    Pharmacol Ther; 1988; 39(1-3):195-201. PubMed ID: 2849123
    [No Abstract]   [Full Text] [Related]  

  • 24. In vitro and in vivo protection against phototoxic side effects of photodynamic therapy by radioprotective agents WR-2721 and WR-77913.
    Dillon J; Kennedy JC; Pottier RH; Roberts JE
    Photochem Photobiol; 1988 Aug; 48(2):235-8. PubMed ID: 2851844
    [No Abstract]   [Full Text] [Related]  

  • 25. Circumvention of the tumor membrane barrier to WR-2721 absorption by reduction of drug hydrophilicity.
    Yuhas JM; Davis ME; Glover D; Brown DQ; Ritter M
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):519-22. PubMed ID: 6286545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro studies on the absorption of WR-2721 by tumors and normal tissues.
    Ritter MA; Brown DQ; Glover DJ; Yuhas JM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):523-6. PubMed ID: 6286546
    [No Abstract]   [Full Text] [Related]  

  • 27. Possible association of radioprotective and chemoprotective aminophosphorothioate drug activity with polyamine oxidase susceptibility.
    Gaugas JM
    J Natl Cancer Inst; 1982 Aug; 69(2):329-32. PubMed ID: 6287074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo dephosphorylation of WR-2721 monitored by 31P NMR spectroscopy.
    Knizner SA; Jacobs AJ; Lyon RC; Swenberg CE
    J Pharmacol Exp Ther; 1986 Jan; 236(1):37-40. PubMed ID: 3001292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs.
    Li C; Wang S; Huang T; Chen N; Ou M
    Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplacental uptake of WR 2721 by the rat embryo.
    Davis ME; Conger AD; Sodicoff M
    Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):575-8. PubMed ID: 3030982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Equilibrium dialysis studies of the binding of radioprotector compounds to DNA.
    Smoluk GD; Fahey RC; Ward JF
    Radiat Res; 1986 Aug; 107(2):194-204. PubMed ID: 3018831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors.
    Rasey JS; Krohn KA; Menard TW; Spence AM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1487-90. PubMed ID: 3019965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M; Faivre S; Raymond E
    Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The cytoprotective agent amifostine (WR-2721): current clinical use and trends in its development].
    Dragojević-Simić V; Dobrić S
    Vojnosanit Pregl; 1996; 53(4):305-10. PubMed ID: 9229947
    [No Abstract]   [Full Text] [Related]  

  • 35. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
    Yuhas JM
    Cancer Res; 1980 May; 40(5):1519-24. PubMed ID: 6245795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for initial clinical trials and future development of radioprotectors.
    Phillips TL
    Cancer Clin Trials; 1980; 3(2):165-73. PubMed ID: 6253097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration.
    Mangold DJ; Miller MA; Huelle BK; Sanchez-Barona DO; Swynnerton NF; Fleckenstein L; Ludden TM
    Drug Metab Dispos; 1989; 17(3):304-10. PubMed ID: 2568913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transdermal absorption of radioprotectors in the rat using permeation-enhancing vehicles.
    Lamperti A; Ziskin MC; Bergey E; Gorlowski J; Sodicoff M
    Radiat Res; 1990 Nov; 124(2):194-200. PubMed ID: 2174175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of WR-2721 in radiotherapy and/or chemotherapy.
    Yuhas JM; Spellman JM; Culo F
    Cancer Clin Trials; 1980; 3(3):211-6. PubMed ID: 6254681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography.
    Bonner HS; Shaw LM
    J Chromatogr B Biomed Sci Appl; 2000 Mar; 739(2):357-62. PubMed ID: 10755379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.